Organon Shareholders Overwhelmingly Approve $14/Share Sale to Sun Pharma
OGN has more than doubled off its 52-week low of $5.69.
Summary
Organon shareholders approved the $14.00 per share acquisition by Sun Pharmaceutical with 98.7% of votes in favor, clearing the path for the merger to close.
Key Events · M&A and Partnerships · OGN
-
Merger Agreement Approved
Shareholders voted 192.8 million shares for, 2.6 million against, and 326,189 abstaining to adopt the merger agreement with Sun Pharmaceutical.
-
Advisory Compensation Vote Passes
The non-binding proposal on merger-related executive compensation was approved with 185.1 million votes for, 9.6 million against, and 980,043 abstaining.
-
Strong Quorum and Overwhelming Support
74.51% of outstanding shares were represented at the special meeting, with 98.7% of votes cast in favor of the merger.
-
Deal Closing Next Step
With shareholder approval secured, the merger is expected to close subject to remaining customary conditions; the $14.00 per share cash deal represents a 3.2% premium to today's price.
Analysis · OGN · Life Sciences
Organon shareholders voted decisively to approve the merger with Sun Pharmaceutical, with 98.7% of votes cast in favor. The vote clears the last major hurdle before closing, despite a last-minute lawsuit attempting to block the meeting. With the stock trading at $13.56, just below the $14.00 deal price, the approval removes uncertainty and signals the deal is on track to close.
At the time of this filing, OGN was trading at $13.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.